JP2013519728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519728A5 JP2013519728A5 JP2012553927A JP2012553927A JP2013519728A5 JP 2013519728 A5 JP2013519728 A5 JP 2013519728A5 JP 2012553927 A JP2012553927 A JP 2012553927A JP 2012553927 A JP2012553927 A JP 2012553927A JP 2013519728 A5 JP2013519728 A5 JP 2013519728A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- trifluoromethyl
- trifluoro
- pyridin
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 7
- 230000036407 pain Effects 0.000 claims 7
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 201000007737 Retinal degeneration Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 230000010370 hearing loss Effects 0.000 claims 3
- 231100000888 hearing loss Toxicity 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 230000004258 retinal degeneration Effects 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- XUNJIMLWMVGTSK-UHFFFAOYSA-N n-[3-cyclobutyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazin-2-yl]-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(C(F)(F)F)=NN2C=1C1CCC1 XUNJIMLWMVGTSK-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- UADMWIAXCFNBCB-UHFFFAOYSA-N 4,4,4-trifluoro-3,3-dimethyl-n-[3-(3-methylbutyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]butanamide Chemical compound C1=CC(C(F)(F)F)=CN2C(CCC(C)C)=C(NC(=O)CC(C)(C)C(F)(F)F)N=C21 UADMWIAXCFNBCB-UHFFFAOYSA-N 0.000 claims 1
- BVXSQBGDDXGTEI-UHFFFAOYSA-N 4,4,4-trifluoro-n-[6-fluoro-3-[4-(trifluoromethyl)pyridin-2-yl]imidazo[1,2-a]pyridin-2-yl]-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(F)=CN2C=1C1=CC(C(F)(F)F)=CC=N1 BVXSQBGDDXGTEI-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- -1 N- (3-cyclopentyl-6- (trifluoromethyl) imidazo [1,2-b] pyridazin-2-yl) -3,4-difluorobenzamide Chemical compound 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 claims 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- JZVWEABTJQFGAO-UHFFFAOYSA-N n-(3-cyclobutyl-6-fluoroimidazo[1,2-a]pyridin-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(F)=CN2C=1C1CCC1 JZVWEABTJQFGAO-UHFFFAOYSA-N 0.000 claims 1
- CVZZPEUPCXZOTD-UHFFFAOYSA-N n-[3-(cyclohexylmethyl)-6-fluoroimidazo[1,2-a]pyridin-2-yl]-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(F)=CN2C=1CC1CCCCC1 CVZZPEUPCXZOTD-UHFFFAOYSA-N 0.000 claims 1
- MDAQRBUMGSARDZ-UHFFFAOYSA-N n-[3-cyclobutyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound FC(F)(F)C(C)(C)C(=O)NC=1N=C2C=CC(C(F)(F)F)=CN2C=1C1CCC1 MDAQRBUMGSARDZ-UHFFFAOYSA-N 0.000 claims 1
- KUNQASPWELZCJC-UHFFFAOYSA-N n-[3-cyclobutyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(C(F)(F)F)=CN2C=1C1CCC1 KUNQASPWELZCJC-UHFFFAOYSA-N 0.000 claims 1
- BPMXKSZIVZAGJP-UHFFFAOYSA-N n-[3-cyclobutyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazin-2-yl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound FC(F)(F)C(C)(C)C(=O)NC=1N=C2C=CC(C(F)(F)F)=NN2C=1C1CCC1 BPMXKSZIVZAGJP-UHFFFAOYSA-N 0.000 claims 1
- BFVKPMBGLXYSOI-UHFFFAOYSA-N n-[3-cyclohexyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(C(F)(F)F)=CN2C=1C1CCCCC1 BFVKPMBGLXYSOI-UHFFFAOYSA-N 0.000 claims 1
- MKHFATNLNIRGBS-UHFFFAOYSA-N n-[3-cyclopentyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-3,4-difluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)NC1=C(C2CCCC2)N2C=C(C(F)(F)F)C=CC2=N1 MKHFATNLNIRGBS-UHFFFAOYSA-N 0.000 claims 1
- HAMPHMHYVVBIAN-UHFFFAOYSA-N n-[3-cyclopentyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(C(F)(F)F)=CN2C=1C1CCCC1 HAMPHMHYVVBIAN-UHFFFAOYSA-N 0.000 claims 1
- AJZCRUVCPQQAIN-UHFFFAOYSA-N n-[3-cyclopropyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound FC(F)(F)C(C)(C)C(=O)NC=1N=C2C=CC(C(F)(F)F)=CN2C=1C1CC1 AJZCRUVCPQQAIN-UHFFFAOYSA-N 0.000 claims 1
- YREYHQNMOUCMQS-UHFFFAOYSA-N n-[3-cyclopropyl-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(C(F)(F)F)=CN2C=1C1CC1 YREYHQNMOUCMQS-UHFFFAOYSA-N 0.000 claims 1
- UMYANQYPGUHAIU-UHFFFAOYSA-N n-[3-cyclopropyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazin-2-yl]-2-(1-methylcyclopentyl)acetamide Chemical compound N1=C2C=CC(C(F)(F)F)=NN2C(C2CC2)=C1NC(=O)CC1(C)CCCC1 UMYANQYPGUHAIU-UHFFFAOYSA-N 0.000 claims 1
- WWDNCUUKKLRWDQ-UHFFFAOYSA-N n-[3-cyclopropyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazin-2-yl]-3,3,3-trifluoro-2,2-dimethylpropanamide Chemical compound FC(F)(F)C(C)(C)C(=O)NC=1N=C2C=CC(C(F)(F)F)=NN2C=1C1CC1 WWDNCUUKKLRWDQ-UHFFFAOYSA-N 0.000 claims 1
- HJHYTJIDVLJSPN-UHFFFAOYSA-N n-[3-cyclopropyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazin-2-yl]-3,4-difluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)NC1=C(C2CC2)N2N=C(C(F)(F)F)C=CC2=N1 HJHYTJIDVLJSPN-UHFFFAOYSA-N 0.000 claims 1
- XOCYWDYKABHPLV-UHFFFAOYSA-N n-[3-cyclopropyl-6-(trifluoromethyl)imidazo[1,2-b]pyridazin-2-yl]-4,4,4-trifluoro-3,3-dimethylbutanamide Chemical compound FC(F)(F)C(C)(C)CC(=O)NC=1N=C2C=CC(C(F)(F)F)=NN2C=1C1CC1 XOCYWDYKABHPLV-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/706,574 | 2010-02-16 | ||
| US12/706,574 US8431608B2 (en) | 2007-08-17 | 2010-02-16 | Heterocycles as potassium channel modulators |
| PCT/US2011/023444 WO2011102964A1 (en) | 2010-02-16 | 2011-02-02 | Heterocycles as potassium channel modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013519728A JP2013519728A (ja) | 2013-05-30 |
| JP2013519728A5 true JP2013519728A5 (https=) | 2014-03-06 |
Family
ID=43734000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553927A Pending JP2013519728A (ja) | 2010-02-16 | 2011-02-02 | カリウムチャンネルモジュレーターとしてのヘテロ環 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8431608B2 (https=) |
| EP (1) | EP2536718A1 (https=) |
| JP (1) | JP2013519728A (https=) |
| CA (1) | CA2788783C (https=) |
| WO (1) | WO2011102964A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2400604T3 (es) * | 2007-08-17 | 2013-04-11 | Icagen, Inc. | Heterociclos como moduladores del canal de potasio |
| MD20170011A2 (ro) * | 2014-08-06 | 2017-08-31 | Pfizer Inc. | Compuşi imidazopiridazinici |
| AR104315A1 (es) * | 2015-04-21 | 2017-07-12 | Glaxosmithkline Ip Dev Ltd | Compuestos de butanamida, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende, su uso para prepararla, y combinación y mezcla que lo comprenden |
| AU2016342027B2 (en) * | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| SG11201811023UA (en) | 2016-06-23 | 2019-01-30 | St Jude Childrens Res Hospital | Small molecule modulators of pantothenate kinases |
| US10183972B2 (en) | 2016-07-14 | 2019-01-22 | University Of South Florida | BK channel-modulating peptides and their use |
| AR110922A1 (es) * | 2017-02-06 | 2019-05-15 | Gilead Sciences Inc | Compuestos inhibidores del vih |
| PL3615019T3 (pl) | 2017-04-26 | 2026-01-19 | Navitor Pharmaceuticals, Inc. | Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie |
| US11370769B2 (en) | 2017-09-07 | 2022-06-28 | Board Of Regents Of The University Of Nebraska | TRPC5 inhibitors and methods of using same |
| WO2019133635A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital | Small molecule modulators of pantothenate kinases |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| WO2020198526A2 (en) * | 2019-03-27 | 2020-10-01 | St. Jude Children's Research Hospital | Small molecule modulators of pank |
| US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| WO2023133256A1 (en) * | 2022-01-07 | 2023-07-13 | Biohaven Therapeutics Ltd. | Pyrazolo[1,5-a]pyridin-2,3-yl amides as kv7 channel activators |
| WO2025067461A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京明德新药研发有限公司 | 杂芳基衍生物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3701780A (en) | 1970-09-18 | 1972-10-31 | Merck & Co Inc | Imidazo(1,2-a)pyridines |
| US4096264A (en) | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
| GB8719368D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Heterocyclic compounds |
| JPH0168375U (https=) | 1987-10-23 | 1989-05-02 | ||
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CA2311483A1 (en) | 2000-06-12 | 2001-12-12 | Gregory N Beatch | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF |
| JP2004517080A (ja) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| CA2504735C (en) | 2002-11-07 | 2009-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| ES2328047T3 (es) | 2004-03-19 | 2009-11-06 | Warner-Lambert Company Llc | Derivados de imidazopiridina e imidazopirimidina como agentes antibacterianos. |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| WO2007056075A2 (en) | 2005-11-02 | 2007-05-18 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| KR20070115502A (ko) | 2006-06-02 | 2007-12-06 | 파크시스템스 주식회사 | 주사 탐침 현미경 및 이를 이용한 측정방법 |
| AU2007279595A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| ES2400604T3 (es) * | 2007-08-17 | 2013-04-11 | Icagen, Inc. | Heterociclos como moduladores del canal de potasio |
| AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| WO2009136663A1 (en) | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
-
2010
- 2010-02-16 US US12/706,574 patent/US8431608B2/en not_active Expired - Fee Related
-
2011
- 2011-02-02 EP EP11703344A patent/EP2536718A1/en not_active Withdrawn
- 2011-02-02 CA CA2788783A patent/CA2788783C/en not_active Expired - Fee Related
- 2011-02-02 JP JP2012553927A patent/JP2013519728A/ja active Pending
- 2011-02-02 WO PCT/US2011/023444 patent/WO2011102964A1/en not_active Ceased
-
2013
- 2013-02-01 US US13/756,759 patent/US9018208B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519728A5 (https=) | ||
| Udupa et al. | The mechanisms of action of deep brain stimulation and ideas for the future development | |
| MX2010001824A (es) | Heterociclos como moduladores de canal de potasio. | |
| Doty et al. | The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? | |
| WO2005025293A3 (en) | Fused ring heterocycles as potassium channel modulators | |
| Maljevic et al. | Potassium channel genes and benign familial neonatal epilepsy | |
| WO2004058704A8 (en) | Quinazolinones as potassium channel modulators | |
| JP2013544277A5 (https=) | ||
| ZA201206715B (en) | Imidazo [1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases | |
| JP2012526735A5 (https=) | ||
| NZ626937A (en) | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors | |
| IN2014DN02177A (https=) | ||
| IN2014DN07384A (https=) | ||
| WO2010106127A3 (en) | Method for therapeutic use | |
| WO2012106343A3 (en) | Hdac inhibitors and therapeutic methods using the same | |
| IL207687A0 (en) | Method of treating ocular diseases by gene therapy | |
| NZ598743A (en) | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | |
| ZA201402056B (en) | (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders | |
| MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
| WO2014015056A3 (en) | Anti-mucus drugs and uses therefor | |
| WO2007009083A3 (en) | Compounds with activity at retinoic acid receptors | |
| EA200900925A1 (ru) | 3-замещённое-[1,2,3]-бензотриазиноновое соединение для увеличения глутаматергических синаптических ответов | |
| WO2013067076A3 (en) | Methods and compositions for neuroprotection | |
| JP2014500885A5 (https=) | ||
| RU2014149123A (ru) | Фенилтриазольное производное и его применение для модуляции ГАМКА-рецепторного комплекса |